TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06712953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the peer assessment group
Description: Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives. Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the peer assessment group
Description: Students in the peer assessment group were paired (by randomization, on their request) to have a teammate of the same sex before the extremity examination experience. In the following process, the students were asked to perform extremity examinations in line with the specified objectives. Students in the standardized patient group were asked to perform extremity examinations per the specified objectives in standardized patient.
Study: NCT06708312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: press needle acupuncture
Description: Placement of press needle on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham press needle acupuncture
Description: Placement of adhesive plaster on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
Study: NCT06714123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senicapoc
Description: administering 30 mg senicapoc a day, in addition to standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets similar in size and color
Study: NCT06712160

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: The number of canals detected by AI
Study: NCT06713317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLB3-002
Description: Recombinant Hyaluronidase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLB3-002
Description: Recombinant Hyaluronidase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl
Description: 0.9% Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl
Description: 0.9% Normal saline
Study: NCT06712875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib and Nivolumab
Description: Trametinib combined with nivolumab (Cohort A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib, trametinib, nivolumab
Description: Dabrafenib + trametinib combined with nivolumab (Cohort B)
Study: NCT06713161

Intervention type: DIAGNOSTIC_TEST
Intervention: NIR-II Probe(i.e ICG-POL6326) incubation solution
Description: After the tissues were incubated with the optimal concentration of the NIR-II probe for the appropriate time, the tissues were washed with the eluate, and then the fluorescence intensity of different tissues was detected to evaluate whether the tissues had cancer tissue invasion.
Study: NCT06710561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN01 for Injection
Description: After each subject was randomly assigned, different doses of SPN01 for Injection (0.02 mg/kg, 0.06 mg/kg, 0.12 mg/kg) were administered intravenously in a single dose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: After each subject was randomly assigned, a single intravenous injection of 0.9% sodium chloride was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN01 for Injection
Description: Colorectal cancer subjects will receive intravenous injection of SPN01 0.06 mg/kg for a single dose.
Study: NCT06710574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-RBD
Description: Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time, keep the original anti Parkinson's drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iRBD
Description: Bifidobacterium triple viable capsule (Bifico Capsule, Shanghai Shangyao Xinyi Pharmaceutical Factory Co., LTD.) 420mg, two times a day, 4 capsules each time; At the same time give the bacillus licheniformis living bacterium capsule (whole bowel capsule, northeast pharmaceutical) 0.5 g, three times a day, two at a time.
Study: NCT06284902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl New Formulation Tablet
Description: New formulation tablet.
Study: NCT06512597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Intervention for Combination Therapy - IBD Coping Strategies Program
Description: psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Time and Attention Control - IBD Support Program
Description: psychosocially credible treatments each comprised of seven 45-minute sessions over a 12-week period, delivered via telemedicine.
Study: NCT06713681

Intervention type: DIAGNOSTIC_TEST
Intervention: TTP-ICG incubation solution
Description: Fresh breast massed and lymph nodes will be incubated with TTP-ICG with different concentrations and times
Study: NCT06712498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Oblique Intercostal Plane Block
Description: After endotracheal intubation, a 22-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
Study: NCT06557252

Intervention type: BEHAVIORAL
Intervention: PDCA training
Description: Improve diagnostic rate
Study: NCT06712498

Intervention type: DRUG
Group type: OTHER
Intervention: control group
Description: No intervention
Study: NCT06711458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-Generated Discharge Instructions
Description: Patient-friendly hospital discharge instructions generated by GPT-4, an advanced natural language processing model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Discharge Instructions
Description: Standard hospital discharge instructions.
Study: NCT06712030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan
Description: Dose titration of Sacubitril/Valsartán to the maximum tolerated dose (maximum 97/103 mg)
Study: NCT06712940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Firearm Safety Training, with Case Management
Description: sssssss
Study: NCT06714110

Intervention type: DEVICE
Intervention: Intramedullary Limb Lengthening Device
Description: The Precice IMLL System is composed of the Precice nail, screws, and uses an external remote controller (ERC) for rod distraction. The Precice IMLL System is designed to fit the anatomy of long bones and is intended to be placed internally in an intramedullary manner. It achieves limb correction through gradual lengthening or compression and providing intramedullary fixation for fractures of long bones.

Intervention type: DEVICE
Intervention: External Fixator Limb Lengthening Device
Description: External fixator devices consist of an external frame (ring, half-ring, monolateral, and rail); bone fixation is accomplished by the transcutaneous bone fixations implants (pins, wires, cables, screws), and the lengthening is accomplished by the vertical components (struts). Generally, femoral lengthening devices are monolateral and tibial lengthening devices have ring or half-ring frames. The external fixators are made of a variety of materials, including stainless steel, titanium, carbon fiber, and aluminum.
Study: NCT06712199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxalidine
Description: Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:
Study: NCT06402331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2265
Description: PSMA ligand radiolabeled with Ac225
Study: NCT05161351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
Study: NCT06712199

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxalidine
Description: Opioid anesthesia group (OBA group) Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and sufentanil 0.3μg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Anesthesia was maintained with propofol 4-12 mg·kg-1·h-1 and remifentanil 0.2-0.5 μg·kg-1·min-1. Sufentanil 10μg was bridaged 30min before the end of surgery. The PCA dosing regimen was sufentanil 2 µg/kg+ dexmedetomidine 2 µg/kg+ ondansetron 24mg.~Reduced-opioid anesthesia group (OFA group)~Anesthesia was induced with propofol 2.5mg·kg-1, rocuronium 0.6mg·kg-1 and esketamine 0.3mg·kg-1. When BIS value reached 40-60, tracheal intubation was performed through visual laryngeal mask airway. Propofol 4-12 mg·kg-1·h-1 and esketamine 0.3-0.5 mg·kg-1·h-1 were pumped to maintain anesthesia during operation. Oxalidine 1.5mg was given in two divided doses of 0.75mg each time with an interval of 10min 30min before the end of surgery. The PCA regimen was as follows:
Study: NCT06711952

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Subjective Cognitive Decline-Questionnaire (SCD-Q)
Description: The SCD-Q is an established instrument to quantify self-perceived cognitive decline. In addition to the self-perceived cognitive complaints, a 24 items questionnaire of informants is part of SCD-Q. The self-reported SCD-Q will be included in the standard health questionnaire that all patients of the memory clinic of the LMU Department of Psychiatry and Psychotherapy are required to complete before the examination date. The health questionnaire will be sent per mail. All routine clinical procedures will remain unchanged.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cognitive Failure Questionnaire (CFQ)
Description: The Cognitive Failure Questionnaire (CFQ) is a questionnaire for measuring self-reported subjective failures in cognition, memory and motor functions in everyday life. The German CFQ consists of 32 items related to everyday possibilities of error, whose frequency in the last six months is to be estimated by means of a five-point rating scale.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: biomarkers
Description: Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer.~Only available clinical and biomarker data will be used (Routine cerebrospinal fluid biomarkers, routine imaging biomarkers).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cognitive Tests
Description: The investigators plan to examine the patients´ visuospatial performance on site with a digital clock-drawing test, which has been validated in large community-based studies.~The Functional Activities Questionnaire (FAQ) shall be filled out by an informant. FAQ is a reliable and valid measure of activities of daily living. The results of the routine neuropsychological tests (Consortium to Establish a Registry for AD, Mini-Mental-State Examination) will be used in the analysis.
Study: NCT06015022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCG)
Description: EGCG is a green tea-derived catechin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in the same capsule with the experimental agent (EGCG).
Study: NCT05715827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAS prostatectomy and RAS cholecystectomy
Description: There are two types of interventions in the study.~Patients indicated for Robotic Assisted Surgery (RAS) for a prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.~Patients indicated for Robotic Assisted Surgery (RAS) for a cholecystectomy will have the RAS surgery using the Medtronic Hugo RAS system.
Study: NCT06603493

Intervention type: OTHER
Intervention: Assessment of sleep disorders
Description: : Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index

Intervention type: OTHER
Intervention: Assessment of sleep disorders
Description: : Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index

Intervention type: OTHER
Intervention: Assessment of Central Sensitization
Description: Central sensitization will be assessed with the Central Sensitization Inventory
Study: NCT06711237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-adhesive resin cement (RC)
Description: Single-unit implant-supported single crowns were cemented to the abutments using a self-adhesive resin cement (RC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-adhesive resin cement (RC)
Description: Single-unit implant-supported single crowns were cemented to the abutments using a self-adhesive resin cement (RC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin-modified glass-ionomer cement (RMGIC)
Description: Single-unit implant-supported single crowns were cemented to the abutments using a resin-modified glass-ionomer cement (RMGIC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin-modified glass-ionomer cement (RMGIC)
Description: Single-unit implant-supported single crowns were cemented to the abutments using a resin-modified glass-ionomer cement (RMGIC). Residual cement was removed, and the restorations were retrieved for analysis of cement remnants.
Study: NCT06714643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The active tDCS protocol consist of 15 excitatory tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC at an intensity of 2 mA. The electrodes are positioned according to the 10-20 electroencephalography system (Anode on F3 and Cathode on F4).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The sham-tDCS intervention consist of a placebo 15 tDCS sessions distributed over 3 weeks (5 sessions per week, from Monday to Friday), at the same time each day, administered by the same operators and under identical experimental conditions. Each session last 30 minutes, with the Anode electrode placed on the left dorsal lateral prefrontal cortex (DLPFC) and the Cathode electrode on the right DLPFC. During the sessions only a 15-second initiation current is applied, providing the patient with the sensation of receiving an electric current on the scalp. Participants will also experience sounds and stimuli similar to those produced by active tDCS.
Study: NCT06127745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discure System
Description: All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
Study: NCT04590781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb18087
Description: Monoclonal bispecific antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb18087
Description: Monoclonal bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb18087 ± Pembrolizumab
Description: XmAb18087 ± Pembrolizumab
Study: NCT06132737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [90Y]Y-PentixaTher
Description: \[90Y\]Y-PTT i.v. injection
Study: NCT04985838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEADS: UP (Helping Ease Anxiety and Depression)
Description: A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
Study: NCT06551584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORCA-T
Description: On Day 0, participants will receive an infusion of Orca-T HSPCs and Orca-T Tregs. On Day +2 or +3 (between approximately 48 to 72 hours of Day 0), patients will receive an infusion of the Orca-T Tcons. There is no dose escalation or de-escalation planned for the Orca-T investigational product.
Study: NCT06540118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 Medically Tailored Meals (MTM) per week
Description: 15 heart-healthy medically tailored meals delivered to participants each week. Meals include breakfast, lunch, dinner, and snack to consume Monday-Friday.
Study: NCT04979858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Mask
Description: The treatment group will receive and use the focal mask.
Study: NCT06540118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 14 Medically Tailored Meals (MTM) per week
Description: 14 heart-healthy medically tailored meals delivered to participants each week. Meals include lunch and dinner to consume Monday-Sunday.
Study: NCT05417204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominothoracic biofeedback
Description: A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abdominothoracic biofeedback
Description: A standard biofeedback technique (3 sessions over a 4-week period) directed at controlling the muscular activity (postural tone) of the abdominal walls, will serve as active intervention in the experimental group, and as a sham intervention in the active comparator group.
Study: NCT05223413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to 200 mmHg to stop blood flow in the arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Simulated RIPC (Sham)
Description: The procedure will be performed by using an electric auto-control device (modified blood pressure monitor for remote ischemic conditioning, Seagull Healthcare Aps, Denmark) for Remote Ischemic Conditioning in the arm. During the inflation period, the blood pressure cuff is inflated to a low pressure not stopping blood flow in the arm.
Study: NCT04769024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LUMEEN Virtual Reality sessions
Description: It will consist in carrying out 12 virtual reality sessions in groups of 6 participants, at a rate of 2 per week for approximately 6 weeks, using the LUMEEN EVASION module. Each session lasts approximately 45 minutes. This module allows the simultaneous broadcasting in virtual reality headsets of 360° videos accompanied by music about different themes: nature, animals, travel, art and live performance.~The course of an EVASION session is as follows:~1. The participants are seated in armchairs in an open environment and sufficiently spaced so that they can move their arms without bumping into each other.~2. The facilitator announces the immersion theme of the session~3. Participants are equipped with virtual reality head-mounted displays.~4. Participants watch the content.~5. The head-mounted displays are removed.~6. A group discussion encouraging participants to share their feelings and what they have learned from the immersion is conducted by the facilitator.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control/non-digital stimulation sessions
Description: It will consist in non-digital stimulation (sensory, social, cognitive, creative) group sessions offering various typical pen-and-paper activities for this public which mainly stimulate language, immediate memory, semantic memory, and visual recognition (e.g., definitions, games of 7 differences, reconstruction of proverbs, quizzes...). A set of activities with instructions will be provided to the investigating centres but the choice of activities in each session will be left to the facilitator's decision in order to adapt the sessions to the participants' desires and abilities, as is usually done in such stimulation groups. The sessions will last 45 minutes and will be offered twice a week for 6 weeks by a facilitator or a caregiver with group care training. The sessions will be organized in groups of 6 participants to match the group size of the intervention groups.
Study: NCT02978651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant (BF2.649)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT04709731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15mg QD
Description: Ponatinib 15 mg tablet, taken orally once daily